Shanghai OPM Biosciences Co., Ltd. (SHA:688293)

China · Delayed Price · Currency is CNY

54.83

+6.04 (12.38%)

At close: Aug 4, 2026

-10.11% (1Y)

Market Cap	7.64B +10.2%
Revenue (ttm)	453.39M +50.5%
Net Income	66.26M +310.5%
EPS	0.30 +112.7%
Shares Out	139.27M
PE Ratio	185.85
Forward PE	84.35
Dividend	0.43 (0.88%)
Ex-Dividend Date	Jul 10, 2026

Volume	5,275,731
Open	49.20
Previous Close	48.79
Day's Range	48.25 - 55.19
52-Week Range	34.13 - 67.80
Beta	0.65
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 31, 2026

About Shanghai OPM Biosciences

Shanghai OPM Biosciences Co., Ltd. provides cell culture media and CDMO services in China and internationally. The company offers cell culture media and feed supplements, such as OPM's CHO-Platform, OPM-293 Platform, OPM-Vac platform, OPM-Hybri Platform, VegaCHO media and feeds, as well as customized cell culture media development services. It also provides end-to-end biologics CDMO services, such as antibody discovery, stable cell line development, cell banking, upstream process development, downstream process development, formulation developm... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2013

Employees 367

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 688293

Full Company Profile

Financial Performance

In 2025, Shanghai OPM Biosciences's revenue was 354.91 million, an increase of 19.40% compared to the previous year's 297.24 million. Earnings were 41.70 million, an increase of 98.07%.

Financial Statements